Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$31.44M+21.6%$25.86M-10.1%$28.77M-5.8%$30.55M+24.0%$24.64M-22.9%
$8.18M-5.9%$8.7M+10.1%$7.9M-7.2%$8.52M+5.4%$8.08M+6.3%
$39.62M+14.7%$34.55M-5.8%$36.67M-6.1%$39.06M+19.4%$32.72M-17.3%
-$39.62M-14.7%-$34.55M+5.8%-$36.67M+6.1%-$39.06M-19.4%-$32.72M+17.3%
$3.85M-4.8%$4.05M-0.9%$4.08M+50.8%$2.71M+0.4%$2.7M-17.3%
-$35.77M-17.2%-$30.51M+6.4%-$32.59M+10.4%-$36.36M-21.1%-$30.02M+17.3%
-$0.34-25.9%-$0.27+18.2%-$0.33+29.8%-$0.47-11.9%-$0.42+17.6%
-$39.35M-15.0%-$34.23M+5.9%-$36.38M+6.1%-$38.75M-19.6%-$32.42M+17.4%
-$39.62M-14.7%-$34.55M+5.8%-$36.67M+6.1%-$39.06M-19.4%-$32.72M+17.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Oric Pharmaceuticals, Inc. profitable?
Oric Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $135.2M over the trailing twelve months.
What is Oric Pharmaceuticals, Inc.'s earnings per share?
Oric Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.41.
Where does Oric Pharmaceuticals, Inc.'s income statement data come from?
Every line is extracted from Oric Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.